Enzo Biochem, Inc.
ENZB
$0.5299
-$0.01-1.85%
OTC PK
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.48M | 29.10M | 30.31M | 31.91M | 33.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.48M | 29.10M | 30.31M | 31.91M | 33.34M |
| Cost of Revenue | 15.71M | 16.08M | 16.86M | 17.28M | 18.78M |
| Gross Profit | 11.77M | 13.02M | 13.46M | 14.63M | 14.56M |
| SG&A Expenses | 20.90M | 20.70M | 21.62M | 24.36M | 28.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.75M | 39.03M | 40.83M | 44.28M | 50.26M |
| Operating Income | -11.28M | -9.93M | -10.52M | -12.37M | -16.92M |
| Income Before Tax | -7.84M | -7.60M | -7.21M | -9.82M | -17.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.84 | -7.60 | -7.21 | -9.82 | -17.55 |
| Earnings from Discontinued Operations | -13.24M | -13.71M | -15.63M | -16.26M | 62.28M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.08M | -21.31M | -22.84M | -26.08M | 44.73M |
| EBIT | -11.28M | -9.93M | -10.52M | -12.37M | -16.92M |
| EBITDA | -9.93M | -8.56M | -9.19M | -11.10M | -15.44M |
| EPS Basic | -0.41 | -0.41 | -0.45 | -0.51 | 0.92 |
| Normalized Basic EPS | -0.09 | -0.09 | -0.09 | -0.12 | -0.22 |
| EPS Diluted | -0.41 | -0.42 | -0.45 | -0.51 | 0.92 |
| Normalized Diluted EPS | -0.09 | -0.09 | -0.09 | -0.12 | -0.22 |
| Average Basic Shares Outstanding | 207.85M | 206.66M | 204.85M | 202.79M | 201.05M |
| Average Diluted Shares Outstanding | 207.85M | 206.66M | 204.85M | 202.79M | 201.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -25.25% | -24.98% | -- | -- | -- |